Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Changling Li"'
Autor:
Xingang Bi, Bingqing Shang, Hongzhe Shi, Aiping Zhou, Changling Li, Jin Zhang, Jianzhong Shou, Shan Zheng, Chuanzhen Cao, Ruiyang Xie, Xiangpeng Kang, Jianhui Ma, Weixing Jiang
Publikováno v:
International Journal of Urology. 29:212-220
OBJECTIVES Metastatic renal cell carcinoma can occur synchronously or metachronously. We characterized the time from diagnosis to systematic therapy as a categorical variable to analyze its effect on the overall survival and first-line treatment effi
Publikováno v:
BMC urology. 22(1)
Objective To investigate the efficacy and complications of surgical treatment in patients with renal cell carcinoma aged ≥ 75 years. Methods From January 2009 to May 2019, we assessed 166 patients aged 75 years and older, who either had radical nep
Autor:
Chuanzhen Cao, Xiangpeng Kang, Bingqing Shang, Jianzhong Shou, Hongzhe Shi, Weixing Jiang, Ruiyang Xie, Jin Zhang, Lianyu Zhang, Shan Zheng, Xingang Bi, Changling Li, Jianhui Ma
Publikováno v:
International braz j urol v.48 n.5 2022
International Braz J Urol
Sociedade Brasileira de Urologia (SBU)
instacron:SBU
International braz j urol, Volume: 48, Issue: 5, Pages: 784-794, Published: 26 AUG 2022
International Braz J Urol
Sociedade Brasileira de Urologia (SBU)
instacron:SBU
International braz j urol, Volume: 48, Issue: 5, Pages: 784-794, Published: 26 AUG 2022
Hypothesis: Nomogram can be built to predict the pathological T3a upstaging from clinical T1a in patients with localized renal cell carcinoma before surgery. Purpose: Renal cell carcinoma (RCC) patients with clinical T1a (cT1a) disease who are upstag
Autor:
Hongzhe Shi, Chuanzhen Cao, Li Wen, Lianyu Zhang, Jin Zhang, Jianhui Ma, Jianzhong Shou, Changling Li
Publikováno v:
BMC urology. 22(1)
Background Several models and markers were developed and found to predict outcome of advanced renal cell carcinoma. This study aimed to evaluate the prognostic value of the ratio of maximum to minimum tumor diameter (ROD) in metastatic clear cell ren
Autor:
Li Wen, Shan Zheng, Jianzhong Shou, Hongzhe Shi, Huijuan Zhang, Changling Li, Jianhui Ma, Weixing Jiang
Publikováno v:
Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment, Vol 20 (2021)
Technology in Cancer Research & Treatment, Vol 20 (2021)
Background: The relationship between the size of the primary tumor and the prognosis of patients with metastatic renal cell carcinoma (mRCC) is unclear. In this study, we aimed to investigate the significance of the size of the primary tumor in mRCC.
Autor:
Jianzhong Shou, Lin Li, Zhendong Xiao, Changling Li, Kaopeng Guan, Shan Zheng, Jun Tian, Zejun Xiao, Xingang Bi, Chuanzhen Cao, Jianhui Ma, Dong Wang, Jing Liang, Huijuan Zhang
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer
BMC Cancer
Background Previous related studies have mainly focused on renal cell carcinoma (RCC) with venous tumor thrombus, specifically inferior vena cava tumor thrombus with renal vein tumor thrombus (RVTT). However, only a few studies have focused on postop
Autor:
Xiaoqi Liu, Wei Zheng, Li Wen, Hongzhe Shi, Aiping Zhou, Jianhui Ma, Changling Li, Shan Zheng, Huijuan Zhang, Weixing Jiang, Dong Wang, Jianzhong Shou
Publikováno v:
Urologic oncology. 39(1)
Few studies have independently investigated the population of patients with synchronous metastatic renal cell carcinoma (smRCC). In this study, we evaluated programmed death protein-ligand 1 (PD-L1) and vascular endothelial growth factor receptor 2 (
Autor:
Jianzhong Shou, Chuanzhen Cao, Changling Li, Hongzhe Shi, Li Wen, Jianhui Ma, Weixing Jiang, Dong Wang
Purpose: Previous reports showed that some patients with renal cell carcinoma (RCC) and renal vein tumor thrombus (RVTT) were misdiagnosed pre-operatively. To improve the accuracy of this diagnosis, the clinical characteristics of RCC with missed RVT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5c65e033d43cd62bc16c5740194a286
Autor:
Jianhui Ma, Jianzhong Shou, Yongkun Sun, Aiping Zhou, Lin Yang, Yan Sun, Jinwan Wang, Yan Song, Chun-Xia Du, Yihebali Chi, Wen Zhang, Changling Li, Chengxu Cui
Publikováno v:
Chinese Medical Journal, Vol 129, Iss 5, Pp 530-535 (2016)
Chinese Medical Journal
Chinese Medical Journal
Background: The metastatic renal cell carcinoma (mRCC) patients treated with upfront cytoreductive nephrectomy combined with α-interferon yields additional overall survival (OS) benefits. It is unclear whether mRCC patients treated with vascular end
Publikováno v:
Clinical genitourinary cancer. 15(1)
Objective Sunitinib is approved multinationally for the first-line treatment of metastatic renal cell carcinoma (mRCC). After mRCC progressed in patients, we escalated the sunitinib dose in selected patients and then retrospectively evaluated the eff